Survival and Description of Care for Patients With Degenerate Vaterian Ampulloma

Ampullary Adenocarcinoma Clinical Trial

— AMPULLOMA  

Official title:

Study of Survival and Description of Care for Patients With Degenerate Vaterian Ampulloma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03800212
• Other study ID #: AMPULLOMA COHORT
• Status: Recruiting
• Start date: July 7, 2017
• Est. completion date: December 15, 2022

Study information

• Verified date: March 2022
• Source: Federation Francophone de Cancerologie Digestive
• Contact: Julien TAIEB, Pr
• Phone: 01 56 09 35 56
• Email: jtaieb75[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

A Vater's ampulloma is a rare digestive tumour which accounts for under 1% of all digestive tumours. The only curative treatment is complete excision (surgical or endoscopic) of the lesions which is possible in 80% of cases , with or without adjuvant treatment. The reference radical treatment is cephalic duodenopancreatectomy (CDP). The indication for adjuvant treatment is still debated: in view of the aggressive nature of the disease and the high recurrence rate, it would appear appropriate to offer adjuvant treatment, although several studies have failed to find any benefit on survival with post-operative radio-chemotherapy, the most widely studied treatment at present, compared to excision alone. At present there are no phase II studies specifically examining medical treatment of degenerated, inoperable Vater's ampullomas. Some groups propose chemotherapies with 5-FU or gemcitabine, analogous to the treatments used for intestinal, pancreatic or biliary tumours, although neither one has been shown to date to be superior to the other, nor have decision-making criteria been clearly established.In conclusion, a national cohort study is proposed to undertake a prospective analysis of the outcome of all patients treated for ampullary adenocarcinoma (particularly survival without recurrence and prognostic indicators for excised tumours and the duration of disease control for tumours treated with palliative chemotherapy). The treatment methods will be left to the free choice of the investigator and all patients may be included, regardless of stage of their disease. In this study, freezing of tumour fragments is encouraged, as this cohort will be supplemented by a later biological study. In order to recruit sufficient patient numbers, the study will be based on participation of the cooperative groups involved in the management of digestive cancers.

Description:

A Vater's ampulloma is a rare digestive tumour which accounts for under 1% of all digestive tumours. In terms of incidence, it is the 3rd most common biliary tract tumour after gallbladder cancer and common bile duct cancer. The incidence of ampullary adenocarcinoma is not well known although it is estimated to be around 0.49 per 100,000 people. The known risk factors are familial adenomatous polyposis (FAP) and Gardner's syndrome, HNPCC (Hereditary Non-Polyposis Colorectal Cancer) syndrome, Peutz-Jeghers syndrome, Crohn's disease and coeliac disease.

Except in its highly localised forms, ampulla of Vater carcinoma carries a poor prognosis. It is a highly lymphophilic disease which commonly metastasises, particularly to the lymph nodes and liver. The prognosis is however considerably better than that of pancreatic adenocarcinoma. In one study which compared 71 ampullomas with 144 adenocarcinomas of pancreatic head, the 5-year survival was 60% for the ampullary carcinomas compared to 20% for pancreatic adenocarcinomas.

More generally, the 5-year survival rate in the literature is between 40-60% and, depending on the study, 10-year survival is approximately 38% .

The only curative treatment is complete excision (surgical or endoscopic) of the lesions which is possible in 80% of cases , with or without adjuvant treatment. The reference radical treatment is cephalic duodenopancreatectomy (CDP). The 5-year survival rate in cases of adenocarcinoma excised by CPD is in the region of 50%, rising to 60-70% if no lymph node invasion is present, compared to 30% when lymph nodes are invaded and median survival is approximately 4.5 years .

The indication for adjuvant treatment is still debated: in view of the aggressive nature of the disease and the high recurrence rate, it would appear appropriate to offer adjuvant treatment, although several studies have failed to find any benefit on survival with post-operative radio-chemotherapy, the most widely studied treatment at present, compared to excision alone . There is only one single randomised study comparing these two forms of management, which shows no benefit in terms of 2 and 5-year survival, although only a small number of patients had an ampullary tumour in this study . The conclusions of several retrospective studies are more subtle, showing results in favour of adjuvant treatment in patients with lymph node disease or a large tumour (T3/T4) .

Some groups have tested the merits of peroperative irradiation. It would appear that this technique does not improve survival, although data on this subject are extremely patchy .

Administration of exclusive adjuvant chemotherapy has been examined in a single randomised study. In this phase III study (ESPAC 3), median overall survival of patients who received adjuvant chemotherapy with FUFOL Mayo for 6 months (n=101) or gemcitabine (n=98) was not significantly improved compared to survival in patients undergoing surgery and not receiving complementary treatment (57.1 versus 43 months, HR= 0.85, p=0.32). A subgroup analysis suggested that the benefit of chemotherapy could be greater in the subgroup of patients with RO resection (p= 0.057, 91% of cases).

Mean survival in patients suffering inoperable tumours is between 9 and 20.4 months depending on the study .

It should be noted however that most of these studies have included tumours other than ampullomas (particularly small bowel adenocarcinomas), making it more difficult to interpret these results, and also that many are old results dating from before the era of modern chemotherapies.

At present there are no phase II studies specifically examining medical treatment of degenerated, inoperable Vater's ampullomas. Some groups propose chemotherapies with 5-FU or gemcitabine, analogous to the treatments used for intestinal, pancreatic or biliary tumours, although neither one has been shown to date to be superior to the other, nor have decision-making criteria been clearly established. One phase II study published in 2009 proposed CAPOX as the reference treatment in light of the promising results obtained. Patients suffering from ampullary cancer in this study however were combined with patients who were suffering from small bowel adenocarcinoma.

In conclusion, a national cohort study is proposed to undertake a prospective analysis of the outcome of all patients treated for ampullary adenocarcinoma (particularly survival without recurrence and prognostic indicators for excised tumours and the duration of disease control for tumours treated with palliative chemotherapy). The treatment methods will be left to the free choice of the investigator and all patients may be included, regardless of stage of their disease. In this study, freezing of tumour fragments is encouraged, as this cohort will be supplemented by a later biological study. In order to recruit sufficient patient numbers, the study will be based on participation of the cooperative groups involved in the management of digestive cancers.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 402
• Est. completion date: December 15, 2022
• Est. primary completion date: December 15, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients aged 18 years and older.

• Histologically-proven adenocarcinoma of the ampulla of Vater which is operable or with locoregional or metastatic recurrence after excision less than 6 months previously.

Exclusion Criteria:

• Patients who cannot be followed up regularly for psychological, social, family or geographical reasons.

• Non-ampullary tumours.

• Non-adenocarcinomatous ampullary tumours.

• Ampullary adenocarcinomas which are metastatic or locally advanced from the outset and inoperable.

Related Conditions & MeSH terms

• Adenocarcinoma
• Ampullary Adenocarcinoma

Intervention

Drug:
• treatment for ampullary adenocarcinoma
all patients treated for ampullary adenocarcinoma (particularly survival without recurrence and prognostic indicators for excised tumours and the duration of disease control for tumours treated with palliative chemotherapy).

Locations

Country	Name	City	State
France	Ch D'Abbeville	Abbeville
France	Chu Hotel Dieu	Angers
France	Ch Annecy Genevois	Annecy
France	Ch Cote Basque	Bayonne
France	Clinique Champeau	Béziers
France	Chu Saint Andre	Bordeaux
France	Polyclinique Bordeaux Nord Aquitaine	Bordeaux
France	Chu Estaing	Clermont-Ferrand
France	Hopitaux Civils de Colmar	Colmar
France	Ch - Sud Francilien	Corbeil-Essonnes
France	Chu Francois Mitterrand	Dijon
France	Chd Vendee	La Roche-sur-Yon
France	Le Kremlin Bicetre	Le Kremlin-Bicêtre
France	Chu Claude Huriez	Lille
France	Hôpital Dupuytren	Limoges
France	Ch Nord Essonne	Longjumeau
France	Chu La Croix Rousse	Lyon
France	Hcl Edouard Herriot	Lyon
France	Hcl Pierre Benite	Lyon
France	CH MACON	Mâcon
France	Hopital de La Timone	Marseille
France	Hopital Saint Joseph	Marseille
France	Ch de Meaux	Meaux
France	Chu Caremeau	Nîmes
France	Chr Orleans	Orléans
France	Chu Avicenne	Paris
France	Chu Cochin	Paris
France	Chu La Pitie Salpetriere	Paris
France	Hopital Europeen Georges Pompidou	Paris
France	Ch Saint Jean	Perpignan
France	CHU Hôpital de la Milétrie	Poitiers
France	Ch Cornouaille	Quimper
France	CH	Reims
France	Ch Saint Malo	Saint-Malo
France	CLINIQUE	Strasbourg
France	Ch Bretagne Atlantique	Vannes

Sponsors (1)

Lead Sponsor	Collaborator
Federation Francophone de Cancerologie Digestive

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival	The time interval between the date of diagnosis of the disease and date of death (all causes). Patients who are alive will be censured at the date of last news.	5 years
Secondary	RECURRENCE FREE SURVIVAL	The time interval between the date of diagnosis of the disease and the date of the recurrence or death (all causes). Patients who are alive without recurrence will be censured at the date of last news.	3 years
Secondary	PROGRESSION FREE SURVIVAL	Time interval between the date of starting treatment and the date of first progression (local or remote, clinical or radiological) or death (all causes). Patients who are alive without progression will be censured at the date of last news. Radiological progression will be defined according to RECIST version 1.1 criteria.	5 years

External Links

•   FFCD page